---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-188867"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T07:12:07.597265+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics prices $60M underwritten offering of common stock and pre-funded warrants

## Summary
- Priced 4,153,717 shares at $12.46/share and pre-funded warrants for 583,483 shares at $12.459 each.
- Gross proceeds ~$60M before underwriting discounts and commissions.
- Offering expected to close on or about July 19, 2023.
- BofA Securities acting as sole bookrunner for the offering.

## SEC filing metadata
- accession: 0001193125-23-188867
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312523188867/0001193125-23-188867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312523188867/d508614d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-188867
- JSON: https://secwatch.observer/filing/0001193125-23-188867.json
- Plain text: https://secwatch.observer/filing/0001193125-23-188867.txt

## Key facts
- Material Agreements
  Janux Therapeutics, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the underwriters named in Schedule A therein valued at $60 million (effective 2023-07-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: BofA Securities, Inc., as representative of the underwriters named in Schedule A therein
  - Value: $60 million
  - Effective: 2023-07-17
  source text: On July 17, 2023, Janux Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the underwriters named in Schedule A therein (the “Underwriters”), relating to the issuance and sale in an underwritten registered direct offering (the “Offering”) by the Company of (i) 4,153,717 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $12.46 per share, and (ii) pre-funded warrants to purchase 583,483 shares of Common Stock at a price of $12.459 per pre-funded warrant (the “Pre-Funded Warrants”), which represents the per share price for the Shares less a nominal $0.001 per share exercise price for each Pre-Funded Warrant. Gross proceeds from the Offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $60 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000119312523188867/0001193125-23-188867-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.